SK282227B6 - Farmaceutický prostriedok na liečenie hyperglykémie - Google Patents

Farmaceutický prostriedok na liečenie hyperglykémie Download PDF

Info

Publication number
SK282227B6
SK282227B6 SK749-95A SK74995A SK282227B6 SK 282227 B6 SK282227 B6 SK 282227B6 SK 74995 A SK74995 A SK 74995A SK 282227 B6 SK282227 B6 SK 282227B6
Authority
SK
Slovakia
Prior art keywords
moxonidine
patients
treatment
parts
plasma glucose
Prior art date
Application number
SK749-95A
Other languages
English (en)
Slovak (sk)
Other versions
SK74995A3 (en
Inventor
Elbert Kaan
Dieter Ziegler
Reinhard Br�Ckner
Original Assignee
Solvay Pharmaceuticals Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Solvay Pharmaceuticals Gmbh filed Critical Solvay Pharmaceuticals Gmbh
Publication of SK74995A3 publication Critical patent/SK74995A3/sk
Publication of SK282227B6 publication Critical patent/SK282227B6/sk

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Dental Preparations (AREA)
  • Fats And Perfumes (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
SK749-95A 1994-07-01 1995-06-06 Farmaceutický prostriedok na liečenie hyperglykémie SK282227B6 (sk)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4423177A DE4423177A1 (de) 1994-07-01 1994-07-01 Antihyperglykämisch wirksame Arzneimittel

Publications (2)

Publication Number Publication Date
SK74995A3 SK74995A3 (en) 1996-05-08
SK282227B6 true SK282227B6 (sk) 2001-12-03

Family

ID=6522064

Family Applications (1)

Application Number Title Priority Date Filing Date
SK749-95A SK282227B6 (sk) 1994-07-01 1995-06-06 Farmaceutický prostriedok na liečenie hyperglykémie

Country Status (23)

Country Link
US (1) US5712283A (no)
EP (1) EP0689837B1 (no)
JP (1) JP3841846B2 (no)
KR (1) KR100366130B1 (no)
CN (1) CN1092961C (no)
AT (1) ATE210444T1 (no)
AU (1) AU691580B2 (no)
CA (1) CA2152998C (no)
CZ (1) CZ287563B6 (no)
DE (2) DE4423177A1 (no)
DK (1) DK0689837T3 (no)
DZ (1) DZ1894A1 (no)
ES (1) ES2167385T3 (no)
FI (1) FI117374B (no)
HU (1) HU226946B1 (no)
IL (1) IL113411A (no)
NO (1) NO307029B1 (no)
NZ (1) NZ270990A (no)
PT (1) PT689837E (no)
RU (1) RU2145857C1 (no)
SK (1) SK282227B6 (no)
UA (1) UA27954C2 (no)
ZA (1) ZA954691B (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977121A (en) * 1995-02-28 1999-11-02 Eli Lilly And Company Use of moxonidine for the treatment of atherosclerosis
PL330637A1 (en) * 1996-06-06 1999-05-24 Lilly Co Eli Agent for and method of treating hypostatic cardiac insufficiency
CA2229123A1 (en) * 1997-02-11 1998-08-11 Mitchell Irvin Steinberg Pharmaceutical agents
DE19722322A1 (de) * 1997-05-28 1998-12-03 Solvay Pharm Gmbh Nephroprotektives Arzneimittel
EP0919234A3 (en) * 1997-10-17 1999-08-25 Eli Lilly And Company Potentiation of pharmaceuticals by moxonidine
US6897019B1 (en) * 1998-04-17 2005-05-24 Tufts College Methods for treating and preventing insulin resistance and related disorders
AU2727400A (en) * 1999-01-29 2000-08-18 Eli Lilly And Company Moxonidine salts
DE19911371A1 (de) 1999-03-15 2000-09-21 Solvay Pharm Gmbh Arzneimittel zur Behandlung von funktionellen Störungen und Erkrankungen der unteren Darmwege, insbesondere von damit einhergehenden abdominalen visceralen Schmerzen
AU2003257418A1 (en) * 2002-06-19 2004-01-06 Solvay Pharmaceuticals Gmbh Medicament for the treatment of diseases requiring inhibition or a reduction in the activity of ph value-regulating bicarbonate transporter proteins
BRPI0415198A (pt) * 2003-10-10 2006-12-05 Solvay Pharm Gmbh composição farmacêutica compreendendo um agonista seletivo do receptor da imidazolina i1 e um bloqueador do receptor da angiotensina ii
RU2542462C2 (ru) * 2013-06-28 2015-02-20 Андрей Владиславович Струтынский Способ коррекции кризового течения гипертонической болезни и абдоминального ожирения

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2849537C2 (de) * 1978-11-15 1983-03-17 Beiersdorf Ag, 2000 Hamburg Substituierte 5-(2-Imidazolin-2-yl)-aminopyrimidine, Verfahren zu deren Herstellung und diese enthaltende Arzneimittel
US4323570A (en) * 1978-11-15 1982-04-06 Beiersdorf Aktiengesellschaft Substituted aminopyrimidines
FR2669927B1 (fr) * 1990-11-29 1994-04-08 Adir Cie Nouveaux derives de guanidine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.

Also Published As

Publication number Publication date
AU691580B2 (en) 1998-05-21
DK0689837T3 (da) 2002-03-11
FI953256A (fi) 1996-01-02
KR100366130B1 (ko) 2003-03-26
SK74995A3 (en) 1996-05-08
HUT72599A (en) 1996-05-28
UA27954C2 (uk) 2000-10-16
DE4423177A1 (de) 1996-01-04
EP0689837A3 (de) 1996-06-05
IL113411A0 (en) 1995-07-31
KR960003729A (ko) 1996-02-23
HU9501900D0 (en) 1995-08-28
JPH0840906A (ja) 1996-02-13
PT689837E (pt) 2002-04-29
NO952624L (no) 1996-01-02
NO307029B1 (no) 2000-01-31
RU2145857C1 (ru) 2000-02-27
ATE210444T1 (de) 2001-12-15
NO952624D0 (no) 1995-06-30
FI117374B (fi) 2006-09-29
JP3841846B2 (ja) 2006-11-08
FI953256A0 (fi) 1995-06-30
CN1092961C (zh) 2002-10-23
CZ287563B6 (en) 2000-12-13
CA2152998C (en) 2002-09-03
DE59509928D1 (de) 2002-01-24
CZ139395A3 (en) 1996-01-17
US5712283A (en) 1998-01-27
AU1775795A (en) 1996-01-18
IL113411A (en) 1999-07-14
ES2167385T3 (es) 2002-05-16
ZA954691B (en) 1996-01-29
HU226946B1 (en) 2010-03-29
EP0689837B1 (de) 2001-12-12
NZ270990A (en) 1997-06-24
CA2152998A1 (en) 1996-01-02
CN1122224A (zh) 1996-05-15
EP0689837A2 (de) 1996-01-03
DZ1894A1 (fr) 2002-02-17

Similar Documents

Publication Publication Date Title
JP7479696B2 (ja) グルコキナーゼ活性化剤およびビグアナイド系血糖降下薬を含む医薬品の組合せ、組成物、配合剤、ならびにその調製方法および使用
US4708868A (en) Oral anti-diabetic pharmaceutical forms and the preparation thereof
KR910004571B1 (ko) 경구용 당뇨병치료 제제를 제조하는 방법
US20140255486A1 (en) Coated Tablet Formulation and Method
SK282227B6 (sk) Farmaceutický prostriedok na liečenie hyperglykémie
US20150250734A1 (en) Stable pharmaceutical compositions of saxagliptin or salts thereof
EP0880967B1 (de) Nephroprotektive Arzneimittel
US5972948A (en) Method of inhibiting hyperglycemia and pharmaceutical composition for use therein

Legal Events

Date Code Title Description
TC4A Change of owner's name

Owner name: ABBOTT PRODUCTS GMBH, HANNOVER, DE

Effective date: 20120920

MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20140606